Key Points
- Director Karen Firestone purchased 8,100 shares of Amylyx (NASDAQ:AMLX) on Dec. 23 at an average price of $12.45, a $100,845 transaction that raised her holdings to 63,100 shares (a 14.73% increase).
- Amylyx has a market cap of about $1.35 billion and recently reported EPS of ($0.37), beating estimates; the stock trades in a 12‑month range of $2.60–$16.96 with 50/200‑day moving averages near $13.72/$10.79.
- Analyst sentiment is mostly positive—several firms have raised price targets (some to $20) and MarketBeat’s average target is $17.25, with the majority of ratings at Buy/Strong Buy.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director Karen Firestone acquired 8,100 shares of the business's stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average cost of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the purchase, the director directly owned 63,100 shares in the company, valued at $785,595. This represents a 14.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Amylyx Pharmaceuticals Stock Performance
AMLX opened at $12.31 on Wednesday. The firm has a market cap of $1.35 billion, a P/E ratio of -6.84 and a beta of -0.34. The business has a 50 day moving average price of $13.72 and a 200 day moving average price of $10.79. Amylyx Pharmaceuticals, Inc. has a twelve month low of $2.60 and a twelve month high of $16.96.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. As a group, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Amylyx Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in Amylyx Pharmaceuticals in the second quarter worth about $45,000. BNP Paribas Financial Markets lifted its stake in Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock worth $47,000 after purchasing an additional 5,904 shares during the period. Legal & General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $47,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at approximately $48,000. Institutional investors and hedge funds own 95.84% of the company's stock.
Wall Street Analysts Forecast Growth
AMLX has been the subject of several research reports. HC Wainwright increased their price objective on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Friday, November 7th. Citigroup increased their price target on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a "buy" rating in a report on Friday, October 17th. Robert W. Baird boosted their price objective on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an "outperform" rating in a report on Thursday, October 16th. Bank of America increased their target price on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, October 3rd. Finally, Lifesci Capital raised Amylyx Pharmaceuticals to a "strong-buy" rating in a research report on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $17.25.
Check Out Our Latest Stock Analysis on AMLX
About Amylyx Pharmaceuticals
(
Get Free Report)
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
